Por: The Hill Health February 01, 2023
Pfizer executives said the company expects a significant drop in revenue in 2023 compared to 2022 as the U.S. government ends its purchase agreement for COVID-19 vaccines and treatments. During its 2022 fourth-quarter earnings call Tuesday, CEO Albert Bourla said he anticipates 2023 to be a “transition year” as advance government purchases end and the company’s COVID-19 vaccine Comirnaty and antiviral treatment Paxlovid start to become... + full article
Newsweek USA Business February 06, 2023
Pfizer's involvement with the 2023 Grammy Awards sparked speculation online, with some viewers wondering how much input the pharmaceutical company had.The annual music ceremony was held at the Crypto.com Arena in Los Angeles, California on Sunday night, with Beyoncé... + más
Here's how to watch the 2023 Grammys on iPhone, iPad, Apple TV, and more | 9to5Mac
Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy. | MarketWatch
MarketWatch USA Business February 04, 2023
Pfizer stock, too, has fallen out of favor, along with other Covid plays. At $44, it’s down 15% this year, making it one of the worst performers in the index. And it’s 30% below its late 2021 peak, badly trailing the rest of the drug group. Now looks like the time to buy... + más
Fact Check: Were the Grammys sponsored by Pfizer? | Newsweek
Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history | CNBC
Newsweek USA Business February 02, 2023
Pharmaceutical giant Pfizer has been accused of making an obscene profit from the coronavirus pandemic after it posted record revenue of more than $100 billion for 2022, a rise of 23 percent on the previous year.The company's COVID products Comirnaty, an mRNA vaccine and... + más
Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics | CNBC
Associated Press USA Business January 31, 2023
Pfizer surprised Wall Street by predicting a bigger-than-expected sales drop this year for two key products: its COVID-19 vaccine and treatment.The drugmaker also released an earnings forecast that starts off below analyst expectations, sending shares lower before the opening... + más
Pfizer says COVID-19 vaccine will cost $110-$130 per dose | ABC News
Ars Technica USA Science December 14, 2022
Navigate Filter by topic Settings Front page layout Site theme - Dec 14, 2022 1:57 pm UTC / Pfizer Chairman and CEO Dr. Albert Bourla speaks onstage at the 2022 SXSW Conference at JW Marriott Austin on March 14, 2022, in Austin. Share this story Senator Elizabeth Warren... + más
CNBC USA Health December 06, 2022
Vials with Pfizer-BioNTech and Moderna coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021.Dado Ruvic Reuters has rejected allegations made by rival that its Covid-19 vaccine is a copy, accusing the Boston biotech company of... + más
Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate
Moderna is suing Pfizer over its coronavirus vaccine | The Verge
CNBC USA Health November 02, 2022
Pfizer CEO Albert Bourla talks during a press conference with European Commission President after a visit to oversee the production of the Pfizer-BioNtech Covid-19 vaccine at the factory of US pharmaceutical company Pfizer, in Puurs, on April 23, 2021.John Thys AFP Getty Images... + más
Pfizer raises 2022 earnings guidance, beats third-quarter expectations | CNBC
Pfizer climbs on strong Q3 results, raised outlook | MarketWatch
About iurex | Privacy Policy | Disclaimer |